Cataract Pipeline: Emerging Non-Surgical Solutions and Leading Companies Shaping the Future of Cataract Treatment | DelveInsight

The therapeutic landscape for Cataract, the leading cause of blindness globally, is undergoing a paradigm shift as researchers and biopharmaceutical companies explore non-surgical and disease-modifying alternatives to conventional cataract extraction surgery. Advances in molecular biology, oxidative stress modulation, and crystallin protein stabilization have opened new avenues for pharmacological intervention. Companies like Nacuity Pharmaceuticals, CGeneTech, and Plex Pharmaceuticals are pioneering efforts to develop novel agents aimed at delaying, halting, or reversing cataract progression.

DelveInsight's "Cataract - Pipeline Insight, 2025" offers a comprehensive analysis of ongoing clinical and preclinical R&D, spotlighting emerging drug candidates, novel mechanisms of action, and innovative delivery systems. From anti-aggregation agents and antioxidants to topical formulations and gene therapy candidates, the pipeline reflects a robust and diversified approach to tackling cataracts beyond surgery.

This report provides a detailed overview of investigational therapies across development phases, highlighting trends in administration routes, formulation innovations, and geographic trial distribution. It also delves into the critical unmet needs, strategic collaborations, regulatory designations (e.g., orphan drug and fast track), and scientific breakthroughs that are poised to redefine the cataract treatment landscape in the coming years.

Interested in learning more about the current treatment landscape and the key drivers shaping the cataract pipeline? Click here: https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cataract Pipeline Report
• DelveInsight's cataract pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for cataract treatment.
• The leading cataract companies include Nacuity Pharmaceuticals, CGeneTech, Melt Pharmaceuticals, Plex Pharmaceuticals, and others are evaluating their lead assets to improve the cataract treatment landscape.
• Key cataract pipeline therapies in various stages of development include NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.
• In March 2025, Bausch + Lomb (NYSE/TSX: BLCO) voluntarily recalled its enVista intraocular lenses following reports of unexplained complications.
• In November 2024, Melt Pharmaceuticals announced positive topline results from its Phase III trial of MELT-300, a non-IV, non-opioid sedation tablet for cataract surgery, meeting FDA-agreed criteria for regulatory submission.
• In June 2024, Alcon (SIX/NYSE: ALC) announced that its UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) received FDA 510(k) clearance, marking the first innovations from its Unity portfolio.

Request a sample and discover the recent breakthroughs happening in the cataract pipeline landscape @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Overview
Cataracts occur when the lens of the eye becomes cloudy, limiting light reaching the retina and impairing vision. They develop slowly over time and may not cause symptoms in the early stages, but without treatment, they worsen and can lead to blindness. In New Zealand, cataracts are a leading cause of vision loss in older adults, primarily due to aging, but can also result from medical conditions, eye injuries, genetics, or medications. Cataracts can also be congenital or develop in children due to infections or trauma.

Common symptoms include cloudy or blurry vision, light sensitivity, difficulty with night driving, and changes in vision or eye prescriptions. If cataracts are suspected, a referral to an ophthalmologist for further examination is recommended. Cataracts can be classified by location, with nuclear cataracts affecting the center of the lens causing significant vision impairment, while cortical cataracts may cause less noticeable issues. Early-stage cataracts may be managed with glasses and better lighting, but surgery is required when cataracts interfere with daily life. Cataract surgery is typically done as a day-stay procedure under local anesthesia with mild sedation.

Find out more about cataract medication @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Treatment Analysis: Drug Profile
NPI 002: Nacuity Pharmaceuticals
Nacuity Pharmaceuticals has developed an intravitreal implant prototype containing NPI-002, a small antioxidant molecule designed to slow cataract progression, along with a proprietary injector. The company has completed non-clinical testing, obtained HREC approval, and plans to begin a Phase 1/2 clinical trial in Australia for NPI-002 in the fourth quarter of 2021.

CGT 1507: CGeneTech
CGT 1507 is a small molecule targeting proteolytic enzymes. Currently in the pre-clinical stage, this drug is being developed for the treatment of cataracts.

Research Programme: Ocular Therapeutics - Plex Pharmaceuticals
Plex Pharmaceuticals is developing CAP 1160, a small molecule targeting HSP27 heat-shock protein modulators, as part of its ocular therapeutics program. The molecule aims to enhance the chaperone-like activity (CLA) of alpha-crystallin (AC), a key protein in the eye lens, to reverse, slow, or prevent cataract formation. By improving AC's CLA, Plex aims to protect damaged lens proteins and prevent aggregation, which is critical for maintaining lens transparency and preventing cataract development.

Learn more about the novel and emerging cataract pipeline therapies @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cataract Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Cataract Pipeline Report
• Coverage: Global
• Key Cataract Companies: Nacuity Pharmaceuticals, CGeneTech, Plex Pharmaceuticals, and others.
• Key Cataract Pipeline Therapies: NPI 002, CGT 1507, Research programme: ocular therapeutics, and others.

Dive deep into rich insights for drugs used for cataract treatment; visit @ https://www.delveinsight.com/report-store/cataract-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cataract Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cataract Pipeline Therapeutics
6. Cataract Pipeline: Late-Stage Products (Phase III)
7. Cataract Pipeline: Mid-Stage Products (Phase II)
8. Cataract Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.